We found that 1) reduced levels of PTPRO correlate with poorer clinical outcomes; and 2) overexpressed PTPRO in lapatinib resistant ERBB2-positive breast cancer cells is capable of reversing lapatinib-resistance. This evidence concerns the gene PTPRO and breast carcinoma.